News
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG Announces the Intended Listing of VERAXA Biotech AG on the NASDAQ Stock Exchange in the 2025 Fiscal Year
Xlife Sciences AG announces the intended listing of VERAXA Biotech AG on the NASDAQ Stock Exchange in the 2025 fiscal year, aiming to advance novel cancer therapies and create value for shareholders -
COMMUNIQUÉ DE PRESSE
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Relief Therapeutics announces final readout of PKU GOLIKE clinical trial showing superior metabolic control during prolonged fasting in PKU patients. Results aim to promote awareness and adoption of PKU GOLIKE -
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Technical interruption to ElecLink operations - Extension update on the expected return to service
Technical interruption on ElecLink operations extended with estimated return to service on 10 February 2025. Group EBITDA target remains unchanged. Getlink holds call on 16 December 2024 for analysts and investors